IP Library Granted Patent US 10,767,161
Granted Patent B2
US 10,767,161 · App. 14/928,383 · Granted Sep 8, 2020

Isolation, expansion and use of clonogenic endothelial progenitor cells

Inventors: Mervin C. Yoder (Indianapolis, IN); David A. Ingram (Indianapolis, IN)
Assignee: Indiana University Research and Technology Corporation
C12N5/0068C12N5/0647C12N5/0692G01N33/5005G01N33/56966A61K2035/124C12N2501/125C12N2501/145C12N2501/22C12N2501/26C12N2502/28C12N2533/54C12N2533/90G01N2333/70589G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,767,161
App. No.
14/928,383
Granted
Sep 8, 2020
Kind
B2
Abstract

A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential—endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.

Claims (5)

1. A method for expanding hematopoietic stem cells (HSCs) ex vivo, the method comprising:

(a) culturing human high proliferative potential-endothelial colony forming cells (HPP-ECFCs) expressing CD31, CD141, CD105, CD146, CD144, vWF, and flk-1, but not CD45 and CD14, and having a nuclear diameter ranging from 8 microns to 10 microns on a collagen coated solid support; wherein one HPP-ECFC replicates into more than 2000 cells in 14 days; and

(b) co-culturing human HSCs with HPP-ECFCs of step (a), thereby expanding HSCs.

2. The method of claim 1 , wherein the HPP-ECFCs are derived from human cord blood cells.

3. The method of claim 1 , wherein the HSCs are derived from human bone marrow.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2016
From: INGRAM, DAVID A.; YODER, MERVIN C.
To: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Reel/Frame 037639/0527 →
Continuity (6)
Division 11055182 · Feb 9, 2005
Provisional Application 60637095 · Dec 17, 2004
Provisional Application 60573052 · May 21, 2004
Provisional Application 60543114 · Feb 9, 2004
Provisional Application 60542949 · Feb 9, 2004
Related Publication 20160115454A1 · Apr 28, 2016